Medication info

Kvarban Tablets 20/160 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletValsartan›160mg / 1 tablet
Manufacturer / importer
Farmgen Science Co., Ltd.
Appearance
Brown oval film-coated tablet
Packaging
30 tablets/box[(10 tablets/PTP x 3)]
Approval status
Expired

MFDS item code 202004114 · Approved 2020.05.29

This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia and atherosclerosis; prevention of cardiovascular events and death
Who takes it
Adults · Children
Adult dose
This medicine should be administered only to adults, and the dosage should be individualized for each patient based on the efficacy and tolerability of each component, valsartan/rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that this medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is required, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed by dose titration over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment. Do not administer this medicine to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Children and adolescents under 18 years: Safety and efficacy have not been established. Children and adolescents under 18 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Farmgen Science Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia and atherosclerosis; prevention of cardiovascular events and death

  • Essential hypertension
  • heart failure
  • heart failure intolerant to ACE inhibitors
  • left ventricular failure
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
View approved original text

This medicine is used for patients who need to take both valsartan and rosuvastatin simultaneously. Valsartan primarily helps in the treatment of essential hypertension and heart failure, and is used for heart failure patients who are intolerant to ACE inhibitors or to reduce the risk of mortality after myocardial infarction. Rosuvastatin is effective in controlling lipid abnormalities such as hypercholesterolemia and mixed hyperlipidemia, and it slows the progression of atherosclerosis. Additionally, it contributes to reducing the risk of stroke, myocardial infarction, and vascular reintervention in patients at high risk for cardiovascular disease. Therefore, this medicine is used for hypertension, heart failure, hyperlipidemia, and reducing the risk of cardiovascular disease.

How to take

Adult dose

This medicine should be administered only to adults, and the dosage should be individualized for each patient based on the efficacy and tolerability of each component, valsartan/rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that this medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is required, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed by dose titration over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment. Do not administer this medicine to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Children and adolescents under 18 years: Safety and efficacy have not been established. Children and adolescents under 18 years: Safety and efficacy have not been established.

Precautions

This medication should not be used during pregnancy. If pregnancy is confirmed, it should be discontinued immediately to prevent serious damage to the fetus and newborn. It is not safe to use this medicine for patients with allergies to it, severely impaired liver or kidney function, or muscle diseases. Older adults or patients with high blood potassium levels, and those with liver function impairment should use this medication with particular caution, and regular liver function tests are recommended, if necessary. This medicine can cause muscle pain or weakness and, rarely, serious muscle damage, so if any unusual symptoms occur in the muscles, consult a doctor immediately. Since this medication lowers blood pressure, symptoms of hypotension or dizziness may occur, and caution is needed when driving or operating machinery. When taking in conjunction with other medications, interactions may occur, so it is essential to inform your physician or pharmacist of any other medications being taken. Regular blood tests to monitor liver function, kidney function, and electrolyte levels are important during the course of treatment with this medication. Safety in children and adolescents under 18 years has not been established, so it is advisable not to use it. In case of overdose, symptoms such as decreased consciousness or low blood pressure may occur, and immediate medical attention should be sought. This medication should be kept out of reach of children, and it is advisable not to transfer it to another container.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver amino transferase levels, increased serum creatine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory disturbance, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral bleeding, vomiting, insulin-dependent diabetes, diabetes complications, leg fracture, spinal fracture, fracture, skin neoplasm, second-degree atrioventricular block, vestibulitis, retinal detachment, unspecified skin tumor-like condition, shingles, disc herniation,hemoptysis, phlegm disease, bronchitis, sensory abnormalities, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, worsening hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reaction, palpitations, worsening angina, auditory disturbances, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal pain, pharyngitis, arthralgia, hypotension, orthostatic dizziness, orthostatic hypotension, kidney function impairment, hyperkalemia, drowsiness, atrial fibrillation, constipation, dry mouth, loss of appetite, malaise, vascular edema, erythema, pruritus, serum sickness, vasculitis, hepatitis, syncope, epistaxis, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased red blood cell volume, decreased hemoglobin, edema, insomnia, rash, decreased libido, myalgia, myopathy, pancreatitis, pruritus, rash, urticaria, weakness, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from light and air. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will ensure the safety and efficacy of the medication.

Appearance and packaging

Appearance

Brown oval film-coated tablet

Package unit

30 tablets/box[(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.